Sorafenib in Combination With Irinotecan in Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors

NCT01715441 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

173

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors

Interventions

DRUG: Sorafenib and irinotecan combination
DRUG: Sorafenib monotherapy
DRUG: Irinotecan monotherapy

Sponsor

Institut du Cancer de Montpellier - Val d'Aurelle